FDA advisory panel rejects widespread Pfizer booster shots, approves for 65+, those at high risk

An influential federal advisory panel has soundly rejected a plan to offer Pfizer booster shots against COVID-19 to most Americans, opting instead to endorse the booster shots only for Americans 65 and over or at high risk for severe disease.